Central-acting. Works on the brain, not blood flow. Melanocortin receptor agonist for when PDE5 inhibitors aren't enough or aren't appropriate. The peptide approach to desire.
PT-141 represents a fundamentally different approach to sexual function. Rather than targeting blood vessels, it activates desire circuits in the brain. It's the first melanocortin agonist approved for sexual dysfunction, opening new possibilities when traditional approaches aren't effective.
PT-141 (bremelanotide, marketed as Vyleesi) was FDA-approved in 2019, marking a paradigm shift in sexual dysfunction treatment. It represents the first central-acting agent approved for this indication:
Book a specialist consultation to discuss whether PT-141 is the right approach for you.